Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.271 -0.049 (-1.12%)
Streaming Delayed Price Updated: 10:58 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. 
Via TheNewswire.com
News headline image
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Granted Key NASH Patent in Israel
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Issues Letter to Shareholders
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.